Update on hemangiomas and vascular malformations

Current Opinion in Pediatrics

Volumn 11, Issue 5, 1999, Pages 457-463

  Powell, Julie ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PREDNISONE;

ANGIOGENESIS; CONGENITAL BLOOD VESSEL MALFORMATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HEMANGIOMA; HUMAN; IMAGING; KASABACH MERRITT SYNDROME; NEUROLOGIC DISEASE; NEVUS FLAMMEUS; PRIORITY JOURNAL; PULSED DYE LASER; REVIEW; STURGE WEBER SYNDROME;

ABNORMALITIES; CHILD; FEMALE; GLUCOCORTICOIDS; HEMANGIOMA; HUMANS; LASERS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PORT-WINE STAIN; PREDNISONE;

EID: 0032852014     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199910000-00015     Document Type: Review

References (41)

1. Esterly NB: Cutaneous hemangiomas, vascular stains and malformations, and associated syndromes. Curr Probl Dermatol 1995, 7:65-108.
2. Mulliken JB, Glowacki J: Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 1982, 69:412-420.
3. Mulliken JB, Young AE, eds: Vascular Birthmarks: Hemangiomas and Vascular Malformations. Philadelphia; W.B. Saunders Company; 1988.
4. Folkman J: Clinical application of research on angiogenesis. N Engl J Med 1995, 333:1757-1763.
5. Arbiser JL: Angiogenesis and the skin: a primer. J Am Acad Dermatol 1996, 34:486-497.
6. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA: Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994, 93:2357-2364.
7. Enjolras O, Mulliken JB: Vascular tumors and vascular malformations (new issues). Adv Dermatol 1998, 13:375-422. This is an excellent review of recent progress in the field of vascular anomalies by two authorities on the subject.
8. Eichenfield LF: Evolving knowledge of hemangiomas and vascular malformations. Arch Dermatol 1998, 134:740-742. The author of this most interesting editorial discusses various areas of progress in our current understanding of vascular anomalies.
9. Dosquet C, Coudert MC, Wassef M, Enjolras O, Drouet L: Intéêt du dosage du bFGF ("basic fibroblast growth factor") pour le diagnostic et le traitement des hémangiomes. Ann Dermatol Venereol 1998, 125:313-316. Results of this study indicate that urinary bFGF levels are useful in identifying proliferative hemangiomas and guiding treatment.
10. Blei F, Walter J, Orlow SJ, Marichuk DA: Familial segregation of heman-giomas and vascular malformations as an autosomal dominant trait. Arch Dermatol 1998, 134:718-722. To this author's knowledge, this is the first report demonstrating familial autosomal dominant inheritance of hemangiomas in six families.
11. Walter JW, Blei F, Anderson JL, Orlow SJ, Spier MC, Marchuck DA: Genetic mapping of a novel familial form of infantile hemangioma. Am J Med Genet 1999, 82:77-83. These authors (Blei et al. [Arch Dermatol 1998, 134:718-22]) have been able to locate the mutation in the families they studied, who had inherited hemangiomas, to chromosome 5q 31-33.
12. Frieden U, Reese V, Cohen D: PHACE syndrome: the association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol 1996, 132:307-311.
13. Orlow SJ, Isakoff SM, Blei F: Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a "beard" distribution. J Pediatr 1997, 131:643-646.
14. Ezekowitz RAB: The relationship between facial and airway hemangiomas: does seeing red bode ill? J Pediatr 1997, 131:514-515.
15. Burrows PE, Robertson RL, Mulliken JB, Bearsdley DS, Chaloupka JC, Ezekowitz RAB, Scott RM: Cerebral vasculopathy and neurologic sequelae in infants with cervicofacial hemangioma: report of eight patients. Radiology 1998, 207:601-607. This is an interesting retrospective review of eight patients with cervicofacial hemangioma and cerebrovascular malformations, of whom four developed symptomatic cerebral infarctions, a complication not previously recognized. Progressive obstructive arterial changes were noted in five out of eight patients who underwent serial MRI.
16. Dubois J, Patriquin HB, Garel L, Powell J, Filiatrault D, David M, Grignon A: Soft-tissue hemangiomas in infants and children: diagnosis using doppler sonography. Am J Roentgen 1998, 171:247-52. Following a prospective study of 116 patients, these authors propose diagnostic ultrasonographic criteria to distinguish between hemangiomas and other vascular malformations or soft-tissue tumors.
17. Dubois J, Garel L, Grignon A, David M, Laberge L, Filiatrault D, Powell J: Imaging of hemangioma and vascular malformations in children. Acad Radiol 1998, 5:390-400. This is a practical and well-illustrated review of radiological imaging for hemangiomas and other vascular malformations.
18. Burrows PE, Laor T, Paltiel H. Robertson RL: Diagnostic imaging in the evaluation of vascular birthmarks. Dermatol Clin 1998, 16:455-488. This is a comprehensive review of the various radiological techniques and their usefulness in the evaluation of vascular anomalies.
19. Tanner JL, Dechert MP, Frieden IJ: Growing up with a facial hemangioma: parent and child coping and adaptation. Pediatrics 1998, 1101:446-452. This is a very interesting and thought-provoking report on the difficulties encountered by families of 25 children with disfiguring facial hemangiomas.
20. Frieden IJ: Which hemangiomas to treat-and how ? Arch Dermatol 1997, 133:1593-1595.
21. Tamayo O, Ortiz DM, Orozco-Covarrubias L, Duran-McKinster C, Mora MA, Avila E, et al.: Therapeutic efficacy of interferon alfa-2b in infants with life-threatening giant hemangiomas. Arch Dermatol 1997, 133:1567-71.
22. Greinwald JH, Burke DK, Bonthius DJ, Bauman NM, Smith RJH: An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolaryngol Head Neck Surg 1999, 125:21-27. This is a prospective, nonrandomized trial on the treatment by interferon alfa-2a of massive or life-threatening hemangiomas in 24 pediatric patients. Treatment effectiveness was as follows (19 patients): complete in 42%, substantial in 16%, intermediate in 26%, and no response in 16%. Five patients (26%) developed neurological abnormalities during treatment: unsteady gait in three patients and fine-motor deficits in two patients. These abnormalities resolved after discontinuation of treatment. The authors stress the importance of neurological evaluation both before and during treatment with interferon alfa and suggest a more gradual increase of the dosage.
23. Barlow CF, Priebe CJ, Mulliken JB, Barnes PD, MacDonald D, Folkman J, Ezekowitz AB: Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998, 132:527-530. This is an important report on the occurrence of spastic diplegia as a complication of interferon alfa-2a in five out of 26 infants treated for severe hemangiomas. The neurologic deficits were reversible in two infants but persistent in the others. Neurological monitoring before and during treatment with interferon alfa is mandatory.
24. Enjolras O, Pouplard F, Beucher A, Ginies JL, Verret JL: Toxicite neurologique de l'interféron alfa-2a au cours du traitement d'un hémangiome céphalique grave. Ann Dermatol Venereol 1996, 123(suppl):144-145.
25. Kasabach JJ, Merritt KK: Capillary hemangioma with extensive purpura: report of a case. Am J Dis Child 1940, 59:1063-1070.
26. Enjolras O, Wassef M, Mazoyer E. Frieden IJ, Prier PN, Drouet L, et al.: Infants with Kasabach-Merritt syndrome do not have "true" hemangioma. J Pediatr 1997, 130:631-640.
27. Sarkar M, Mulliken JB, Kozakewich HPW, Robertson RL, Burrows PL: Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform angioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997, 100:1377-1366.
28. Vin-Christian K, McCalmont JH, Frieden IJ: Kaposiform hemangioendothelioma: an aggressive, locally invasive vascular tumor that can mimic hemangioma of infancy. Arch Dermatol 1997, 133:1573-1578.
29. el-Dessouky M, Azmy AF, Raine PA, Young DG: Kasabach-Merritt syndrome. J Pediatr Surg 1988, 23:109-111.
30. Reid DR, Maria BL, Branc WE, Quisling RG, Hoangk B: Central nervous system perfusion and metabolism abnormalities in Sturge-Weber syndrome. J Child Neural 1997, 12:218-221.
31. Fischbein NJ, Barkovich AJ, Wu Y, Berg BO: Sturge-Weber syndrome with no leptomeningeal enhancement on MRI. Neuroradiology 1998, 40:177-188.
32. Griffiths PD, Boodram MB, Blaser S, Armstrong D, Gilday DC, Harwood-Nash D: 99 m Technitium HMPAO [hexamethylpropyleneamineoxime] imaging in children with the Sturge-Weber syndrome: a study of nine cases with CT and MRI correlation. Neuroradiology 1997, 39:219-224.
33. Pinton F, Chiron C, Enjolras O, Motte J, Syrota A, Dulac O: Early single photon emission computed tomography in Sturge-Weber syndrome. J Neurol Neurosurg Psychiatry 1997, 63:616-621.
34. Moore GJ, Slovis TL, Chugani HT: Proton magnetic resonance spec-troscopy in children with Sturge-Weber syndrome. J Child Neurol 1998, 13:332-335. In this study, the authors describe the usefulness of a new noninvasive technique with which they study cerebral biochemistry in six children with Sturge-Weber syndrome.
35. van der Horst CMAM, Koster PHL, de Borgie CAJM, Bossuyt PMM, van Gemert MJC: Effect of the timing of treatment of port-wine stains with the flash-lamp-pumped pulsed-dye laser. N Engl J Med 1998, 338:1028-1033. The conclusions of this prospective study of 100 patients are in contradiction with the previously-held notion that earlier laser treatment of PWSs is associated with better outcome. However, the study includes very few children younger than 1 year of age, which may affect the results.
36. 2).
37. Troilius A, Wrangsjö B, Ljunggren B: Potential psychological benefits from early treatment of port-wins stains in children. Br J Dermatol 1998, 139:59-65.
38. Renfro L, Geronemus RG: Anatomical differences of port-wine stains in response to treatment with the pulsed dye laser. Arch Dermatol 1993, 129:182-188.
39. Waldorf HA, Alster TS, McMillan K, Kauvar ANB, Geronemus RG, Nelson JS: Effect of dynamic cooling on 585-nm pulsed dye laser treatment of port-wine stain birthmarks. Dermatol Surg 1997, 23:657-62.
40. Haedersdal M, Efsen J, Gniadecka M, Fogh H, Keiding J, Wulf HC: Changes in skin redness, pigmentation, echostructure, thickness and surface contour after 1 pulsed dye laser treatment of port-wine stains in children. Arch Dermatol 1998, 134:175-81.
41. Vikkula M, Boon LM, Mulliken JB, Olsen BR: Molecular basis of vascular anomalies. Trends Cardiovasc Med 1998, 8:281-292. This is an extensive review of the recent discoveries in molecular genetics relating to vascular anomalies.